{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:20:10Z","timestamp":1787948410344,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare lenvatinib (LEN) and atezolizumab plus bevacizumab (Atezo + Bev) as first-line therapy in super-older adults (\u226580 years) with hepatocellular carcinoma (HCC) and evaluate whether early relative dose intensity (RDI) is associated with outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included super-older adults initiating LEN or Atezo + Bev between May 2018 and August 2025. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and adverse events. Inverse probability of treatment weighting and multivariable Cox regression were performed. Within the LEN cohort, a day 56 landmark analysis evaluated the prognostic significance of 8-week RDI (RDI8\u2005\u2265\u200575% vs. &lt;75%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median OS was 15.6 and 10.7 months with LEN and Atezo + Bev [hazard ratio: 0.77, 95% confidence interval (CI): 0.42\u20131.41], whereas median PFS was 6.73 and 9.73 months, respectively (hazard ratio: 1.18, 95% CI: 0.65\u20132.17). IPTW and multivariable analyses yielded similar results. Within the LEN cohort, RDI8 greater than or equal to 75% was independently associated with improved OS (30.8 vs. 14.7 months; adjusted hazard ratio: 0.23, 95% CI: 0.07\u20130.73,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.013). Grade greater than or equal to 3 adverse events occurred in 37 and 50% of the LEN and Atezo + Bev cohorts, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although LEN and Atezo + Bev showed no statistically significant difference in real-world survival in this exploratory cohort, these findings require validation in larger studies. Higher early LEN dose intensity was consistently associated with improved survival and may represent an important therapeutic consideration in super-older adults with HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/meg.0000000000003263","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:00:14Z","timestamp":1787947214000},"page":"1213-1223","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Early lenvatinib dose intensity is associated with survival in super-older adults (\u226580 years) with hepatocellular carcinoma: a real-world comparison with atezolizumab\u2013bevacizumab"],"prefix":"10.1097","volume":"38","author":[{"given":"Masamichi","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"R1-20260828","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260828","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)00516-4","article-title":"The World report on ageing and health: a policy framework for healthy ageing.","volume":"387","author":"Beard","year":"2016","journal-title":"Lancet"},{"key":"R3-20260828","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2152\/jmi.67.40","article-title":"Area-based medicine in the Super-Ageing Society in Japan.","volume":"67","author":"Inoue","year":"2020","journal-title":"J Med Invest"},{"key":"R4-20260828","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R5-20260828","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20260828","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"R7-20260828","doi-asserted-by":"crossref","first-page":"e0231828","DOI":"10.1371\/journal.pone.0231828","article-title":"Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.","volume":"15","author":"Kirino","year":"2020","journal-title":"PLoS One"},{"key":"R8-20260828","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.21873\/anticanres.13710","article-title":"Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma.","volume":"39","author":"Takahashi","year":"2019","journal-title":"Anticancer Res"},{"key":"R9-20260828","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/hepr.13720","article-title":"Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.","volume":"52","author":"Tokunaga","year":"2022","journal-title":"Hepatol Res"},{"key":"R10-20260828","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R11-20260828","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R13-20260828","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models.","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R14-20260828","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers14071747","article-title":"Atezolizumab\/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study.","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R15-20260828","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cam4.4854","article-title":"Does first-line treatment have prognostic impact for unresectable HCC? \u2013 Atezolizumab plus bevacizumab versus lenvatinib.","volume":"12","author":"Hiraoka","year":"2023","journal-title":"Cancer Med"},{"key":"R16-20260828","doi-asserted-by":"crossref","first-page":"e70217","DOI":"10.1002\/cam4.70217","article-title":"Frontline evaluation: atezolizumab-bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up-to-seven criteria.","volume":"13","author":"Kimura","year":"2024","journal-title":"Cancer Med"},{"key":"R17-20260828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","article-title":"Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.","volume":"180","author":"Casadei-Gardini","year":"2023","journal-title":"Eur J Cancer"},{"key":"R18-20260828","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"key":"R19-20260828","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/hepr.13748","article-title":"Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a landmark analysis.","volume":"52","author":"Hatanaka","year":"2022","journal-title":"Hepatol Res"},{"key":"R20-20260828","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41577-019-0180-1","article-title":"Mechanisms underlying T cell ageing.","volume":"19","author":"Goronzy","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"R21-20260828","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC.","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"R22-20260828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system.","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat Immunol"},{"key":"R23-20260828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.","volume":"6","author":"Elias","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R24-20260828","doi-asserted-by":"crossref","first-page":"100577","DOI":"10.1016\/j.esmoop.2022.100577","article-title":"The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression.","volume":"7","author":"Kim","year":"2022","journal-title":"ESMO Open"},{"key":"R25-20260828","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people.","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"R26-20260828","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach \u2013 the ALBI grade.","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R27-20260828","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology.","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MEG.0000000000003263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:00:17Z","timestamp":1787947217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MEG.0000000000003263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000003263","relation":{},"ISSN":["0954-691X","1473-5687"],"issn-type":[{"value":"0954-691X","type":"print"},{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"2026-04-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}